vidarabine phosphate has been researched along with Lymphoma, Non-Hodgkin in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (9.09) | 18.7374 |
| 1990's | 13 (59.09) | 18.2507 |
| 2000's | 7 (31.82) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bewsher, CJ; Braylan, RC; Hei, DL; Hudson, JK; Lynch, JW; Mendenhall, NP; Rimzsa, LM; Staab, EV | 1 |
| Budman, DR; Cascella, P; D'Amico, P; Eisenberg, P; Etcubanas, E; Ferrer, JM; Hinderling, PH; Lichtman, SM; Melikian, A; Musgrave, K; O'Mara, V; Williams, GJ; Zervos, G | 1 |
| Hotta, T; Minami, H; Morishima, Y; Ogawa, Y; Ogura, M; Sasaki, Y; Seriu, T; Tobinai, K; Watanabe, T | 1 |
| de Wolf-Peeters, C; Eghbali, H; Hagenbeek, A; Hoskin, PJ; Kalmus, J; MacLennan, K; Marcus, R; Monfardini, S; Negrouk, A; Schott, A; Staab-Renner, E; Teodorovic, I; van Glabbeke, M; Vitolo, U | 1 |
| Biedermann, HG; Bretzel, G; Büttner, DW; Frosch, M; Hamperl, WD; Heldwein, K; Laregina, D; Löscher, T; Tappe, D | 1 |
| Binet, JL | 1 |
| Aboulafia, DM; Demirer, T | 1 |
| Bayle, C; Bendahmane, B; Bennaceur, A; Bosq, J; Carde, P; Decaudin, D; Hayat, M; Munck, JN; Nedellec, G; Tertian, G; Venuat, AM | 1 |
| Barbui, T; Coiffier, B; Foran, JM; Hiddemann, W; Johnson, SA; Lister, TA; Norton, AJ; Radford, JA; Rohatiner, AZ; Tollerfield, SM; Wilson, MP | 1 |
| Abdulkadyrov, KM; Beresneva, IA; Gershanovich, ML; Medvedeva, NV; Samuskevich, IG; Zaritskiĭ, AIu | 1 |
| Cullen, MH; de Takats, PG; Foran, JM; Johnson, SA; Klein, M; Kraus, C; Lister, TA; Orchard, J; Oscier, D; Tighe, M | 1 |
| Child, JA; Johnson, PW; Johnson, SA; Morgan, GJ; Prentice, AG; Rule, S; Smith, GM; Tollerfield, SM; Wareham, E | 1 |
| Culligan, D; Cunningham, D; Gieschen, H; Johnson, S; Klein, M; Orchard, JA; Oscier, D; Parker, A | 1 |
| Cabanillas, F; Hagemeister, FB; Keating, MJ; McLaughlin, P; Plunkett, WK; Redman, JR; Rodriguez, MA; Swan, F; Velasquez, WS | 1 |
| Cheson, BD | 2 |
| Balcerzak, S; Grever, M; Kraut, E; Leiby, J; Malspeis, L; Metz, E; Neidhart, J | 1 |
| Cassileth, P; Hochster, H | 1 |
| Catovsky, D; Davis, CL; Lister, TA; Mehta, AB; Ranson, M; Rohatiner, AZ; Rule, S; Smith, OP; Whelan, JS | 1 |
| Grever, MR; Kraut, EH; Leiby, JM; Malspeis, L; Metz, EN; Snider, KM | 1 |
| Clark, GM; Diehl, V; Lathan, B; von Hoff, DD | 1 |
2 review(s) available for vidarabine phosphate and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Fludarabine phosphate in chronic lymphoproliferative diseases. The French Group on CLL.
Topics: Antimetabolites, Antineoplastic; Clinical Trials, Phase II as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Vidarabine Phosphate; Waldenstrom Macroglobulinemia | 1993 |
New chemotherapeutic agents for non-Hodgkin's lymphomas.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Humans; Lymphoma, Non-Hodgkin; Pentostatin; Vidarabine Phosphate | 1991 |
12 trial(s) available for vidarabine phosphate and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Phase II study of fludarabine combined with interferon-alpha-2a followed by maintenance therapy with interferon-alpha-2a in patients with low-grade non-hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Interferon alpha-2; Interferon-alpha; Lymphoma, Non-Hodgkin; Middle Aged; Recombinant Proteins; Remission Induction; Vidarabine Phosphate | 2002 |
Phase I and pharmacokinetic study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Female; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Vidarabine Phosphate | 2006 |
Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Prednisone; Prospective Studies; Vidarabine Phosphate; Vincristine | 2006 |
Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Disease-Free Survival; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Vidarabine Phosphate | 1998 |
Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Survival Analysis; Vidarabine Phosphate; Waldenstrom Macroglobulinemia | 1999 |
[The use of fludarabine phosphate (Fludara) to treat chronic B-cell lymphocytic leukemia and non-Hodgkin's lymphoma resistant to standard chemotherapy].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Treatment Outcome; Vidarabine Phosphate | 1998 |
Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Biological Availability; Cross-Over Studies; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prospective Studies; Vidarabine Phosphate | 1999 |
FLUDAP: salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Pilot Projects; Recurrence; Salvage Therapy; Survival Rate; Vidarabine Phosphate | 2000 |
The bioavailability of oral fludarabine phosphate is unaffected by food.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Biological Availability; Cross-Over Studies; Female; Food-Drug Interactions; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prospective Studies; Treatment Outcome; Vidarabine Phosphate | 2001 |
Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Evaluation; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Treatment Outcome; Vidarabine Phosphate | 1992 |
A comprehensive phase I and II clinical investigation of fludarabine phosphate.
Topics: Adult; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Evaluation; Humans; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Neoplasms; Vidarabine Phosphate | 1990 |
Fludarabine phosphate for the treatment of low grade lymphoid malignancy.
Topics: Antineoplastic Agents; Drug Evaluation; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Vidarabine; Vidarabine Phosphate | 1991 |
8 other study(ies) available for vidarabine phosphate and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: a prospective dose adjustment study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Curve; Creatinine; Dose-Response Relationship, Drug; Female; Humans; Injections, Intravenous; Kidney Failure, Chronic; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Metabolic Clearance Rate; Middle Aged; Prospective Studies; Vidarabine Phosphate | 2002 |
Subcutaneous Taenia crassiceps infection in a patient with non-Hodgkin's lymphoma.
Topics: Aged, 80 and over; Albendazole; Animals; Cyclophosphamide; Female; Humans; Immunocompromised Host; Larva; Lymphoma, Non-Hodgkin; Praziquantel; Subcutaneous Tissue; Taenia; Taeniasis; Vidarabine Phosphate | 2006 |
Fatal bone marrow necrosis following fludarabine administration in a patient with indolent lymphoma.
Topics: Aged; Antimetabolites, Antineoplastic; Biopsy; Bone Marrow; Eosinophils; Fatal Outcome; Humans; Lymphoma, Non-Hodgkin; Male; Necrosis; Vidarabine Phosphate | 1995 |
Fludarabine phosphate--looking forward.
Topics: Antimetabolites, Antineoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Vidarabine Phosphate | 1990 |
Fludarabine phosphate: an effective therapy for lymphoid malignancies.
Topics: Antimetabolites, Antineoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Vidarabine Phosphate | 1990 |
Fludarabine phosphate therapy of non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Female; Humans; Leukopenia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nervous System Diseases; Remission Induction; Survival Rate; Vidarabine Phosphate | 1990 |
Phase II trial of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in non-Hodgkin's lymphoma: prospective comparison of response with deoxycytidine kinase activity.
Topics: Adult; Aged; Antineoplastic Agents; Arabinonucleotides; Deoxycytidine Kinase; Drug Administration Schedule; Drug Evaluation; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Phosphotransferases; Prospective Studies; Vidarabine Phosphate | 1987 |
Cytotoxic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5-monophosphate (fludarabine, NSC 312887) in a human tumor cloning system.
Topics: Antimetabolites, Antineoplastic; Arabinonucleotides; Breast Neoplasms; Cell Survival; Dose-Response Relationship, Drug; Female; Humans; Lymphoma, Non-Hodgkin; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vidarabine Phosphate | 1988 |